• ALOX5 Deficiency Drives Ferroptosis Escape in Bladder Cancer

  2026-07-23

  This study uncovers how ALOX5 loss confers resistance to ferroptosis in bladder cancer, facilitating tumor progression. By elucidating the transcriptional regulation of ALOX5 and its clinical relevance, the work highlights new prognostic and therapeutic targets for advanced bladder cancer.

• Kv1.3 Blockade Redefined: Mechanistic and Strategic Frontier

  2026-07-22

  Explore how Psora 4, a highly selective Kv1.3 blocker from APExBIO, is reshaping immunomodulatory research by integrating advanced insights into T cell calcium signaling, effector memory T cell inhibition, and the nuanced role of channel subunits like KCNE4. This article bridges mechanistic breakthroughs with actionable strategies for translational researchers, outlining protocol parameters and the evolving landscape of Kv1.3-targeted immunomodulation in autoimmunity models.

• Fluo-4 AM Calcium Assay Kit: Decoding Scaffold Fiber Density

  2026-07-22

  Explore how the Fluo-4 AM Calcium Assay Kit enables unprecedented insight into fiber density–driven mechanotransduction in tissue engineering. This article delivers advanced analysis of calcium dynamics in live cells, with actionable guidance for innovative scaffold design.

• Iron-Dependent KDM4D Regulates MSC Fate via PI3K-Akt-Foxo1 A

  2026-07-21

  This study demonstrates that iron-dependent activity of the histone demethylase KDM4D governs the balance between quiescence and activation of mesenchymal stem cells (MSCs) through the PI3K-Akt-Foxo1 signaling pathway. The findings establish a mechanistic link between iron deficiency, impaired MSC mobilization, and bone loss, with significant implications for metabolic bone disease research.

• HPF: Advancing Precision hROS Detection for Translational On

  2026-07-21

  Explore the mechanistic role, validation strategies, and translational impact of HPF (hydroxyphenyl fluorescein) as a next-generation probe for highly reactive oxygen species (hROS) in cancer therapy research. This article bridges molecular insight with strategic guidance for cell biologists, highlighting HPF’s pivotal role in multimodal ROS-driven theranostics, with contextual reference to emerging nanodynamic therapies and workflow optimization.

• Reliable Real-Time PCR with HotStart™ 2X Green qPCR Master M

  2026-07-20

  This article provides scenario-driven guidance for biomedical researchers and technicians facing challenges in cell-based qPCR workflows. By examining evidence and real lab situations, it demonstrates how HotStart™ 2X Green qPCR Master Mix (SKU K1070) from APExBIO delivers reproducibility and precision for gene expression, nucleic acid quantification, and RNA-seq validation.

• High-Throughput Blood-Brain Barrier Model: Predictive Advanc

  2026-07-20

  This study establishes a high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, integrating lysosomal trapping correction for enhanced prediction of CNS drug permeability. The approach demonstrates robust in vitro-in vivo correlation, offering a reliable, scalable platform for early-stage central nervous system (CNS) drug screening.

• Olaparib (AZD2281): Applied Protocols in DNA Damage Response

  2026-07-19

  Olaparib (AZD2281) from APExBIO empowers researchers to dissect DNA repair mechanisms with rigor and flexibility, especially in BRCA-deficient cancer models. This article distills cutting-edge workflows, troubleshooting tips, and new synergy insights for DNA damage response and tumor radiosensitization studies.

• 6-Thioguanine Suppresses EV71 via BIRC3-Mediated Autophagy I

  2026-07-18

  This study demonstrates that 6-thioguanine significantly inhibits EV71 replication by targeting BIRC3-mediated autophagy pathways in vitro. The findings provide mechanistic insight and a strong rationale for further preclinical evaluation of thioguanine as a candidate therapy for severe hand, foot, and mouth disease.

• Imatinib (STI571) in Next-Gen Kinase Assays: Precision, Limi

  2026-07-17

  Explore how Imatinib (STI571) enables advanced kinase inhibition assays and signal transduction research. This article uniquely connects cutting-edge mass spectrometry imaging innovations to practical protocol optimization for cancer biology and kinase pathway studies.

• Applied Biotin (Vitamin B7) Workflows: Labeling, Metabolism,

  2026-07-17

  Biotin (Vitamin B7) is not only a metabolic coenzyme but also a gold-standard labeling reagent, driving innovation from carboxylase assays to advanced protein biotinylation. This article delivers actionable workflows, protocol refinements, and troubleshooting strategies leveraging APExBIO’s high-purity Biotin for robust, reproducible results in biochemical and molecular research.

• PCI-32765 Ibrutinib: Workflows and Troubleshooting in B-Cell

  2026-07-16

  Ibrutinib (PCI-32765) from APExBIO is a gold-standard irreversible BTK inhibitor, enabling precise dissection of B-cell receptor signaling and disease mechanisms. This article details advanced experimental workflows, data-driven protocol enhancements, and troubleshooting strategies to unlock robust results in chronic lymphocytic leukemia and autoimmune disease models.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis and MAPK Res

  2026-07-16

  JNK-IN-7 enables precise dissection of JNK-driven signaling in inflammation and apoptosis models, surpassing traditional inhibitors in selectivity and workflow reproducibility. This guide translates recent experimental breakthroughs into actionable protocols and troubleshooting strategies for advanced MAPK pathway research.

• Catalpol’s Multi-Target Protection in Cardio-Cerebrovascular

  2026-07-15

  This comprehensive review synthesizes the mechanistic and translational roles of catalpol, a natural iridoid glycoside, in mitigating cardio-cerebrovascular diseases (CVDs). The insights highlight catalpol’s multi-pathway modulation—antioxidant, anti-inflammatory, and anti-apoptotic—for attenuating cardiac and cerebrovascular injury, identifying it as a promising candidate for further translational and experimental research.

• Angiotensin II-HIF-1α-HILPDA Axis Drives Radioresistance in

  2026-07-15

  The reference study reveals how local angiotensin II (Ang II) suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma (NPC) via the HIF-1α-HILPDA signaling axis. These findings highlight actionable molecular targets for increasing NPC radiosensitivity, suggesting that combined inhibition of Ang II signaling and ferroptosis induction could improve radiotherapy efficacy.

445 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page